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ABBREVIATIONS 
AEC alveolar epithelial cell 
α-SMA alpha-smooth muscle actin 
BMP bone morphogenetic protein 
cDNA complementary deoxyribonucleic acid 
COPD chronic obstructive pulmonary disease 
CPFE combined pulmonary fibrosis and emphysema 
CTGF connective tissue growth factor 
DMEM Dulbecco’s modified Eagle’s medium 
ECM extracellular matrix 
EDA extra type III domain A (fibronectin) 
EMT epithelial-to-mesenchymal transition 
ERK extracellular signal-regulated kinase 
FEV1 forced expiratory volume in one second 
FVC forced expiratory vital capacity 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GATA-6 transcription factor binding to the (A/T)GATA(A/G) consensus sequence 
GDF growth and differentiation factor 
ICC immunocytochemistry 
IF immunofluorescence 
IFN-γ interferon gamma 
IHC immunohistochemistry 
IPF idiopathic pulmonary fibrosis 
JNK c-Jun N-terminal kinase 
miRNA microRNA 
PAI-1 plasminogen activator inhibitor-1 
PBS phosphate-buffered saline 
PLA proximity ligation assay 
RNA ribonucleic acid 
rRNA ribosomal ribonucleic acid 
RT room temperature 
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RT-PCR reverse transcriptase polymerase chain reaction 
SD standard deviation 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
siRNA small interfering RNA; silencing RNA 
Smad vertebrate gene product; named after related Caenorhabditis elegans gene Sma 
and Drosophila gene mothers against decapentaplegic (Mad) 
TGF transforming growth factor 
UIP usual interstitial pneumonia 
WB western blot 
Wnt gene product; named after related Drosophila gene wingless and mouse 
mammary tumour virus Int1 
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ABSTRACT 
 
This thesis focuses on transforming growth factor (TGF)-β signalling system in the human 
lung. Two lung parenchymal diseases, idiopathic pulmonary fibrosis (IPF) and chronic 
obstructive pulmonary disease (COPD), were studied. In IPF, persistent fibroblasts and 
extracellular matrix accumulate in the lung parenchyma, causing thickening of the 
parenchyma with subsequent difficulties in breathing. An opposing process in the lung 
parenchyma is seen in emphysematous lung in COPD, where alveolar wall damage causes 
loss of alveolar structure and shortness of breath. 
The aim of the study was to examine alterations in TGF-β signalling activity in 
pathologically distinct areas of damaged lung tissue (fibrosis, emphysema). Furthermore, 
TGF-β signalling properties, i.e. storage and activation, as well as the role of transcription 
factor GATA-6 in the pathogenesis of IPF were studied. Finally, novel treatment options for 
IPF were sought. 
The studied materials were tissue samples from patient lung biopsies along with a selection of 
commercial and primary lung cell lines. Gene expression levels and protein (co)localization 
as well as cell differentiation were studied with modern molecular biology tools. Reporter 
cells and high-throughput screening were used in the search for new candidate drugs for IPF. 
The results of the screen were validated in a mouse model of silica-induced pulmonary 
fibrosis. 
The results showed that TGF-β signalling activity varies within pathologically distinct areas 
of the lung, with emphysematous areas showing decreased and fibrotic areas showing 
increased signalling activity. In fibrotic tissue, this is accompanied by a significant increase 
in the storage and activation of latent TGF-β. 
It is a common belief that the fibroblastic foci (i.e. aggregates of (myo)fibroblasts) in IPF 
consist of actively proliferating cells. Here, this view was challenged as fibroblastic foci were 
found to consist of quiescent, non-proliferating and non-apoptotic cells. These cells, however, 
were still responsive to TGF-β signals, suggesting that they keep contributing to the 
extracellular matrix accumulation. Transcription factor GATA-6 was found to be a crucial 
mediator of the TGF-β-induced cell differentiation of epithelial cells and fibroblasts towards 
a myofibroblast-like phenotype. 
For the first time in IPF research, high-throughput screening technology was used in the 
search for novel treatment options. The results were promising: primary in vitro data revealed 
one compound which affected TGF-β family signalling and showed biologically significant 
antifibrotic effects in a mouse model of fibrosis.  The data obtained here offers a starting 
point for further studies. 
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TIIVISTELMÄ (FINNISH SUMMARY) 
 
Idiopaattisessa keuhkofibroosissa (idiopathic pulmonary fibrosis, IPF) soluja ja 
soluväliainetta alkaa tuntemattomasta syystä kertyä keuhkokudokseen. Tämän seurauksena 
keuhkokudos paksuuntuu ja kaasujenvaihto vaikeutuu. Vastakkainen ilmiö on 
keuhkoahtaumataudille (chronic obstructive pulmonry disease, COPD) tyypillinen 
emfyseema eli keuhkojen laajentuma, jossa keuhkorakkularakenne on tuhoutunut. 
Tämän tutkimuksen tavoitteena oli selvittää TGF-β-sytokiinin (transforming growth factor-
beta) signaalinvälityksessä tapahtuvia muutoksia vaurioituneiden keuhkojen eri alueilla 
(fibroosi, emfyseema). Lisäksi tutkittiin TGF-β:n varastointia ja aktivaatiota sekä 
transkriptiofaktori GATA-6:n roolia keuhkofibroosin patogeneesissä. Lopuksi etsittiin uusia 
mahdollisuuksia keuhkofibroosin lääkehoitoon. 
Tutkimusmateriaaleina käytettiin keuhkokudosnäytteitä, niistä eristettyjä primäärisiä 
solulinjoja sekä lisäksi kaupallisia solulinjoja. Geenien ilmentymistä, proteiinien sijaintia 
kudoksessa sekä solujen erilaistumista tutkittiin modernein ja monipuolisin 
molekyylibiologian menetelmin. Molekyylikirjastojen seulonnassa hyödynnettiin 
reportterisoluja ja tehoseulontateknologiaa. 
Tutkimustulokset osoittivat, että TGF-β-signalointiaktiivisuus vaihtelee vaurioituneen 
keuhkokudoksen eri alueilla: se oli laskenut keuhkokudosnäytteiden emfysemaattisilla 
alueilla ja kohonnut fibroottisilla alueilla. Fibroottisessa keuhkokudoksessa havaittiin 
merkittävää nousua myös TGF-β:n varastointiin ja aktivaatioon liittyvän proteiinin 
ilmentymisessä. 
Perinteisesti on uskottu, että fibroblastifokukset eli fibroosille tyypilliset 
(myo)fibroblastisolujen muodostamat pesäkkeet muodostuvat aktiivisesti jakautuvista 
soluista. Tutkimustulostemme mukaan näiden pesäkkeiden solut näyttäisivät kuitenkin olevan 
lepotilassa, ts. niillä ei havaittu aktiivista solunjakautumista tai ohjelmoitua solukuolemaa. 
Tästä huolimatta myofibroblastit olivat säilyttäneet kykynsä ottaa vastaan TGF-β-välitteisiä 
signaaleja, mikä viittaisi siihen, että ne edelleen ylläpitävät soluväliaineen tuottoa. 
Transkriptiofaktori GATA-6:n todettiin olevan oleellinen osa TGF-β:n indusoimaa, epiteeli- 
ja fibroblastisolujen erilaistumista ohjaavaa signaalinvälitysreittiä. 
Tehoseulontateknologiaa käytettiin ensimmäistä kertaa IPF-tutkimuksessa. Tulokset olivat 
lupaavia: molekyylikirjastojen seulonnoissa löytyi yksi TGF-β-perheen signalointiin 
vaikuttava yhdiste, jolla pystyttiin osoittamaan biologisesti merkittäviä antifibroottisia 
vaikutuksia keuhkofibroosin hiirimallissa. 
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REVIEW OF THE LITERATURE 
1 TGF-β & BMP SIGNALLING 
1.1 The TGF-β superfamily 
Thirty-three structurally related polypeptide growth factors are classified as members of the 
transforming growth factor (TGF)-β superfamily. These include TGF-βs, activins and 
inhibins, nodal, Leftys, bone morphogenetic proteins (BMPs), and growth/differentiation 
factors (GDFs) (de Caestecker 2004). They are phylogenetically divided into two main 
groups: the TGF-β/activin and BMP/GDF branches (de Caestecker 2004). These signalling 
molecules have wide-ranging and diverse roles in development, differentiation, and 
homeostasis. 
 
1.2 Formation and activation of TGF-β 
In mammals, there are three closely related isoforms of TGF-β, designated TGF-β1, -β2, and 
-β3. They have similar properties in vitro but distinct effects in vivo (Annes et al. 2003). 
Thus far, TGF-β, GDF-8, and BMP-10 are the three unique members of this superfamily 
found to be synthesized as inactive precursors (de Caestecker 2004; Sengle et al. 2011).  
TGF-β is a 25 kD protein, composed of two 12.5 kD subunits held together by disulfide 
bonds (Assoian et al. 1983). The three TGF-βs are all synthesized as homodimeric 
proproteins (Annes et al. 2003).  The TGF-β propeptides, also known as the latency-
associated peptides (LAPs), are cleaved before the secretion from the cell (Gentry et al. 
1988). However, they remain noncovalently bound to TGF-β, retaining TGF-β in a latent 
form incapable of binding to signalling receptors (Gentry et al. 1987). 
A third component of the large latent TGF-β complex (Figure 1) is a disulfide-linked latent 
TGF-β binding protein (LTBP), which plays a critical role in the assembly and efficient 
secretion of the latent TGF-β. Through interactions with extracellular matrix proteins, LTBPs 
also regulate the storage and activation of TGF-β (Miyazono et al. 1991; Todorovic & Rifkin 
2012). Thus far, four LTBPs have been identified (LTBP-1, -2, -3, and -4). Of these, LTBPs-
1, -3, and -4 interact with latent TGF-β, whereas LTBP-2 does not (Saharinen & Keski-Oja 
2000). 
Latent TGF-β, bound to LTBPs, is targeted to fibrillin microfibrils and fibronectin in the 
extracellular matrix (ECM) (Dallas et al. 2005; Isogai et al. 2003; Massam-Wu et al. 2010; 
Taipale et al. 1996). For activation, the large latent TGF-β complex needs to be released from 
the ECM, and TGF-β liberated from the latent complex. TGF-β activation can be done via 
proteolytic or non-proteolytic mechanisms which result, respectively, in either cleavage or 
conformational changes of the latent TGF-β complex, allowing the active TGF-β peptide to 
interact with its receptors on cell surface. The proteolytic mechanisms include plasmin 
(Lyons et al. 1990), matrix metalloproteinase-9 and -2 (Yu & Stamenkovic 2000), and 
integrin αvβ8 (Mu et al. 2002); thrombospondin-1 (Crawford et al. 1998) and integrin αvβ6 
(Munger et al. 1999) work in a non-proteolytic manner. In this context, fibrillins are 
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interesting because in addition to LTBP binding sites, fibrillins also contain binding sites for 
integrin receptors (Olivieri et al. 2010) and integrin-mediated TGF-β activation is suggested 
to be important in the pathogenesis of IPF (Chandramouli et al. 2011; Goodwin & Jenkins 
2009). However, TGF-β activation in IPF is still not well understood. 
 
 
 
 
 
Figure 1.The large latent TGF-β complex consists of three components: TGF-β dimer, LAP 
dimer, and LTBP. TGF-β can be activated, i.e. liberated from the latent complex, via several 
mechanisms (marked with □). Integrins and thrombospondin-1 bind to recognition sequences 
in LAP (RGD and LSKL, respectively). Modified from Koli et al. 2008. 
 
 
 
1.3 The expression and bioavailability of BMP 
BMP-7 is secreted as a stable complex of processed growth factor dimer noncovalently 
associated with its two prodomain propeptide chains (Gregory et al. 2005). The possibility of 
forming similar complexes in vivo has also been suggested for BMP-2, -4, -9, and -10 (Brown 
et al. 2005; Sengle et al. 2008). Of these, BMP-10 complex needs activation like TGF-β and 
GDF-8 complexes (Sengle et al. 2011). The function of the propeptides is to target the 
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growth factors to ECM macromolecules, such as fibrillin microfibrils (Gregory et al. 2005; 
Sengle et al. 2008). 
Contrary to TGF-β signalling activity, BMP signalling activity is regulated on the level of 
bioavailability. This is done by a number of BMP-binding proteins such as Noggin, Chordin, 
and Gremlin (Umulis et al. 2009). The binding proteins can either inhibit or promote BMP 
signalling by affecting BMP release, transport through tissues, and receptor binding (Umulis 
et al. 2009). 
 
1.4 Receptors in TGF-β and BMP signalling 
Active TGF-βs and BMPs signal through single-pass transmembrane serine/threonine kinase 
proteins, referred to as the TGF-β receptor family. Based on their structural and functional 
properties, the TGF-β receptor family is divided into two subfamilies: type I (55 kD) and type 
II (70 kD) receptors (Massague 1998). 
A heteromeric receptor complex consists of two distinct transmembrane proteins (Attisano & 
Wrana 2002). Ligand binding induces the type I and type II receptors to associate, which 
leads to a unidirectional phosphorylation event in which the type II receptor phosphorylates 
the type I receptor, thereby activating its intracellular kinase domain (Attisano & Wrana 
2002). The activated type I receptor then activates Smad family proteins or other intracellular 
mediators which carry the signal to the nucleus (Massague 1998). 
 
1.5 Smad protein classification 
After binding to their respective receptors, TGF-β and BMPs signal within the cell through 
the Smad family of transcription activators, which in mammals includes eight proteins. 
Smads have been named after related Drosophila gene mothers against decapentaplegic 
(Mad) and Caenorhabditis elegans gene Sma. Smads are divided into three classes: the 
receptor-regulated R-Smads, inhibitory I-Smads, and a co-Smad. A schematic diagram of 
TGF-β/BMP signalling through Smad proteins is presented in Figure 2. 
R-Smads (Smad-1, -2, -3, -5, -8) are directly phosphorylated by type I receptors on two 
conserved serine residues at the C-terminus. Smad-2 and Smad-3 are phosphorylated in the 
presence of TGF-β ligand (Leask & Abraham 2004). Smad-1, Smad-5 and Smad-8 are 
substrates for bone morphogenetic protein receptor I (BMP RI) (Miyazono et al. 2010), and 
are thus mediators of BMP signals. 
Phosphorylation stimulates R-Smads to accumulate in the nucleus as heteromeric complexes 
with Smad-4, which is the only member of the co-Smad class and shared by BMP and TGF-
β/activin signalling pathways (Miyazono et al. 2010). 
The third class, the I-Smads (Smad-6 and -7), antagonize TGF-β and BMP signalling by 
competing for receptor binding and thus preventing R-Smad phosphorylation, by competing 
with co-Smad for complex formation, and by inhibiting the Smad-DNA complex formation 
(Leask & Abraham 2004; Miyazono et al. 2010) (Figure 2). TGF-β rapidly induces 
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expression of Smad-7, suggesting that Smad-7 may participate in a negative feedback loop to 
control TGF-β responses (Nakao et al. 1997). In a similar fashion, the expression of Smad-6 
is regulated by BMP-activated Smad1/5 (Ishida et al. 2000). 
 
 
 
 
 
Figure 2. A simplified diagram of the TGF-β and BMP pathways with their corresponding 
Smad proteins. TGF-β and BMP receptors phosphorylate R-Smads, which form a complex 
with Smad-4. This complex is shuttled into the nucleus where it binds to chromatin and, 
together with other transcription factors, regulates target gene expression. Modified from 
Miyazono et al. 2010; Moustakas & Heldin 2009. 
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1.6 Function of Smads 
Smads do not themselves activate transcription but are rather believed to assist in the 
formation of a functional transcriptional complex on target promoters with other transcription 
factors (Attisano & Wrana 2002). In the basal state, Smads exist as homo-oligomers in the 
cytoplasm (Massague 1998). Upon ligand activation of the receptor complex, the type I 
kinase phosphorylates specific Smads, which then form a complex with Smad-4 and move 
into the nucleus. In the nucleus, these complexes activate target genes by binding to specific 
promoter elements (Massague 1998). The cellular responses and transcriptional outcome is 
dependent on interactions with other transcription factors, co-activators, and co-repressors, 
whose identity varies depending on the promoter or cell type of interest (Leask & Abraham 
2004; Mu et al. 2012). 
Inman et al. (2002) have shown that during the active signalling, Smads are constantly 
shuttling between the nucleus and the cytoplasm. The bulk of nuclear Smad-2 and Smad-3 is 
not targeted for degradation, but are continuously being dephosphorylated which results in 
their dissociation from Smad-4. The Smads recycle back to the cytoplasm independently. If 
the receptors are still active in the cytoplasm, the R-Smads are rephosphorylated, form 
complexes with Smad-4, and return to the nucleus. If the receptors are no longer active, the 
R-Smads are retained in the cytoplasm. 
 
1.7 Non-Smad signalling pathways 
TGF-βs and BMPs have a complicated intracellular signalling network with both Smad and 
non-Smad signalling pathways. In Smad-dependent pathways, phosphorylated Smad proteins 
carry their signals to the nucleus. In addition to Smads, ligand binding to TGF-β receptors 
can activate other proteins such as the small GTPase Ras or mitogen-activated protein kinases 
ERK (extracellular signal-regulated kinase), p38 and JNK (c-Jun N-terminal kinases) 
(Moustakas & Heldin 2005). The activation of these alternative signalling pathways can 
result in either Smad phosphorylation or induce responses unrelated to Smads (Derynck & 
Zhang 2003; Nohe et al. 2002; Sovershaev et al. 2011; Tian et al. 2012). Non-Smad 
signalling proteins have three general mechanisms, which are presented in Figure 3. 
Interestingly, these two signalling systems are parallel. TGF-β can activate e.g. JNK in two 
ways: rapid, Smad-independent JNK activation is followed by sustained, Smad-dependent 
JNK activity (Engel et al. 1999). It has also been shown that when BMP-2 binds to a 
preformed receptor complex, it activates the Smad pathway, whereas BMP-2-induced 
recruitment of receptors activates a Smad-independent p38 MAPK pathway (Nohe et al. 
2002). Thus, the cellular responses to TGF-β and BMPs are often defined by the balance 
between direct activation of Smads and mitogen-activated protein kinase pathways (Derynck 
& Zhang 2003).  
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Figure 3. A schematic diagram of 
Smad and non-Smad signalling. 
The Smad pathway starting from 
the ligand-receptor complex and 
ending in the nucleus is illustrated 
by thin black arrows. Non-Smad 
signalling mechanisms are 
illustrated by thick grey arrows. 
There are three distinct but 
interrelated modes of action: 
1) non-Smad signalling pathways 
directly modify the Smads; 
2) Smads directly interact and 
modulate the activity of other 
signalling proteins and transmit 
signals to other pathways; and 
3) the TGF-β receptors directly 
interact with or phosphorylate 
non-Smad proteins, initiating 
parallel signalling that cooperates 
with the Smad pathway. Modified 
from Moustakas & Heldin 2005. 
 
 
 
 
 
 
 
1.8 Transcription factors 
Smad proteins form complexes with DNA-binding transcription factors (Attisano & Wrana 
2002). Numerous transcription factors can mediate the signals of TGF-β family members but 
the repertoire of expressed transcription factors differs between tissue and cell type 
(Moustakas & Heldin 2009). This enables the complexity of transcriptional regulation of 
target genes (Ikushima & Miyazono 2012). Examples of transcription factors linked to TGF-β 
signalling in the lungs are presented in Table 1. 
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Table 1. Examples of transcription factors that are linked to TGF-β signalling in the lungs. 
Transcription factor Alternative name Function Reference 
Early growth response 
factor (Egr)-1, -2 
Egr-1 = Krox-20 
Egr-2 = Krox-24 
mediators of TGF-β-induced 
profibrotic responses, e.g. 
collagen expression 
Bhattacharyya et al. 
2008; Fang et al. 
2011 
Yin Yang 1 (YY1)  regulates fibrogenesis by 
increasing α-SMA and 
collagen expression 
Lin et al. 2011 
SNAI1, -2 SNAI1 = Snail 
SNAI2 = Slug 
mediators of  TGF-β-induced 
EMT 
Jayachandran et al. 
2009 
Twist  contributes to EMT Pozharskaya et al. 
2009 
Thyroid transcription 
factor (TTF)-1 
Nkx2.1 inhibits TGF-β-mediated EMT 
in lung cancer 
Saito et al. 2009 
GATA-6  mediates TGF-β-induced cell 
differentiation 
Leppäranta et al. 
2010 
α-SMA, alpha-smooth muscle actin;  EMT, epithelial-to-mesenchymal transition (see section 2.4.2) 
 
 
1.8.1 GATA-6 
GATA transcription factors regulate the expression of various genes required for 
developmental processes and tissue-specific functions. Six GATA transcription factors have 
been identified in vertebrates. Based on their expression patterns, they have been divided into 
two subfamilies: GATA-1, -2, and -3 function in hematopoietic cells whereas GATA-4, -5, 
and -6 function in mesoderm- and endoderm-derived organs (Maeda et al. 2005). 
Each of the GATA proteins contains a highly conserved DNA binding domain consisting of 
two zinc fingers, which bind to a consensus sequence (A/T)GATA(A/G) (Molkentin 2000). 
The GATA-6 gene has two transcriptional start sites, which enables the production of both 
the L-type (long) and the S-type (short) isoforms in the same tissue-specific and 
developmental stage-specific pattern (Brewer et al. 1999; Takeda et al. 2004). 
GATA-6 plays an important role in the establishment of the endodermally derived bronchial 
epithelium in lungs, lung cell differentiation, and regulation of gene expression (Morrisey et 
al. 1998; Shaw-White et al. 1999). It is expressed in embryonic lung tissue with a precise 
temporal-spatial control which is required to enable normal lung morphogenesis (Liu et al. 
2003; Suzuki et al. 1996). 
GATA-6 is also expressed in the adult lungs (Suzuki et al. 1996). Within the respiratory 
epithelium, GATA-6 has been implicated in the transcriptional regulation of genes such as 
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surfactant protein (SP)-A, and thyroid transcription factor-1 (TTF-1) (Bruno et al. 2000; 
Shaw-White et al. 1999). 
 
1.9 TGF-β family in development and disease 
TGF-β family members play a key role in normal development, homeostasis, and tissue 
repair. Either gain or loss of these signalling processes underlies numerous disorders (Figure 
4). 
During development, various factors regulate cell fate, i.e. the commitment of stem and 
progenitor cells to differentiation pathways. TGF-β family members play a key role in this 
process, both in cell lineage selection and progression of differentiation (Derynck & Akhurst 
2007). They are also able to induce transdifferentiation, which means redirecting the 
differentiation of cells in particular lineage. This kind of cell plasticity is an essential and 
well-orchestrated event in normal tissue and organ development (Derynck & Akhurst 2007). 
In adults, TGF-β helps to maintain tissue homeostasis by controlling the proliferation, 
apoptosis, and microenvironmental interactions of epithelial, endothelial, neuronal, and 
haematopoietic cell lineages (Siegel & Massague 2003). 
However, problems arise when TGF-β signalling is disturbed. This can be the result of either 
mutations in TGF-β family ligands, receptors, and signalling proteins, or dysregulation of 
signalling in the TGF-β pathway itself (Horbelt et al. 2012; Santibanez et al. 2011). Aberrant 
TGF-β signalling contributes to a wide range of disorders, including cardiovascular, fibrotic, 
inflammatory, pulmonary, bone, and muscle diseases as well as cancer (Horbelt et al. 2012; 
Santibanez et al. 2011). 
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Figure 4. Examples of the roles of TGF-β family members in human development, homeostasis, and diseases (August & Suthanthiran 2006; 
Derynck & Akhurst 2007; Gordon & Blobe 2008; Santibanez et al. 2011; Siegel & Massague 2003). EMT, epithelial-to-mesenchymal transition 
(see section 2.4.2). 
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2 IDIOPATHIC PULMONARY FIBROSIS (IPF) 
2.1 IPF and other interstitial lung diseases 
The idiopathic interstitial pneumonias are a heterogeneous group of diffuse parenchymal lung 
diseases. Idiopathic indicates unknown cause and interstitial pneumonia refers to 
involvement of the lung parenchyma by varying combinations of fibrosis and inflammation 
(American Thoracic Society & European Respiratory Society 2002). The interstitium 
includes the space between the epithelial and endothelial basement membranes and it is the 
primary site of pathologic tissue accumulation in idiopathic interstitial pneumonias. However, 
these disorders frequently affect not only the interstitium, but also the airspaces, peripheral 
airways, and vessels along with their respective epithelial and endothelial linings (American 
Thoracic Society & European Respiratory Society 2002). 
Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial 
pneumonias (Meltzer & Noble 2008). It is characterized by the formation of scar tissue 
within the lungs in the absence of any known provocation (Meltzer & Noble 2008). IPF is a 
chronic, progressive disease with a median survival of 2-5 years following diagnosis (Meltzer 
& Noble 2008; Raghu et al. 2011; Scotton & Chambers 2007). 
 
2.2 Clinical features and diagnosis of IPF 
The patients’ age at onset is usually greater than 60 years (Johnston et al. 1997). 
Breathlessness and chronic dry, non-productive cough are the most prominent symptoms 
(American Thoracic Society & European Respiratory Society 2002). Spirometry reveals 
decreased measures of forced vital capacity (FVC) and forced expiratory volume in one 
second (FEV1); the ratio of FEV1/FVC remains normal (or increased) in IPF (Meltzer & 
Noble 2008). 
The accurate diagnosis of IPF requires a compatible clinical history, the exclusion of other 
known causes of interstitial lung diseases - such as drug toxicity, environmental exposures, or 
connective tissue disease - and the presence of a so-called UIP (usual interstitial pneumonia; 
see section 2.4.1) pattern on high-resolution computed tomography (Raghu et al. 2011). In 
typical cases of IPF, the diagnosis can be made without a surgical lung biopsy; however, it is 
often necessary to make a definitive diagnosis. 
 
2.3 Incidence and prevalence of IPF 
IPF is estimated to affect approximately 5 million people worldwide (Meltzer & Noble 2008). 
Both incidence and prevalence of IPF are generally higher among men than women (Johnston 
et al. 1997; Raghu et al. 2006). Data from around the world demonstrates that IPF favours no 
particular race, ethnic group or social environment (Meltzer & Noble 2008). 
The world-wide incidence of IPF is estimated at 7-10 / 100 000 / year (Pardo & Selman 2002; 
Raghu et al. 2006). In the US, using narrow criteria, prevalence is estimated to be 14 / 
100 000 (Raghu et al. 2006). In Finland prevalence is 16-18 /100 000 (Hodgson et al. 2002), 
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which corresponds to roughly 1000 patients. According to the European Union definition - 
any disease affecting fewer than 5 people in 10 000 - IPF is considered to be a rare disease 
(http://ec.europa.eu/health/rare_diseases/policy/index_en.htm). 
Although sporadic cases constitute the majority of cases, familial cohorts of IPF are also 
reported (Meltzer & Noble 2008). For example in Finland, a cohort of familial cases was 
strongly clustered in a certain area in Eastern Finland, suggesting a founder effect among 
them (Hodgson et al. 2002). 
 
2.4 Characteristic features of IPF 
2.4.1 Usual interstitial pneumonia pattern 
IPF is associated with the histopathologic pattern known as usual interstitial pneumonia 
(UIP), which consists of normal lung architecture alternating with patches of pulmonary 
parenchymal fibrosis, fibroblastic foci, and architectural distortion (Meltzer & Noble 2008; 
Raghu et al. 2011). In addition, histology of IPF/UIP lungs can show mild interstitial 
inflammation (Raghu et al. 2011; Scotton & Chambers 2007). The alveolar epithelium in UIP 
can undergo various morphological alterations. Especially over the fibrotic lesions, the 
normal epithelial cell layer is often replaced with either activated, hyperplastic epithelial cells 
or elongated and flattened fibroblast-like epithelial cells (Selman & Pardo 2006). 
The pathological alterations in pulmonary tissue are reflected to radiological findings. In high 
resolution computed tomography, the UIP pattern is characterized by the presence of reticular 
opacities. Honeycombing, i.e. clustered cystic airspaces, is common and critical for making a 
definite diagnosis. The distribution of UIP on high resolution computed tomography is 
characteristically subpleural with basal predominance, and often patchy (Raghu et al. 2011). 
 
2.4.2 Epithelial-to-mesenchymal transition 
Epithelial-to-mesenchymal transition (EMT) is a process whereby fully differentiated 
epithelial cells undergo transition to a mesenchymal phenotype giving rise to fibroblasts and 
myofibroblasts. It can be viewed as an extreme form of cell plasticity, which is characterized 
by loss of epithelial markers (e.g. E-cadherin and zonula occludens-1), cytoskeletal 
reorganization, transition to a spindle-shaped morphology concurrent with acquisition of 
mesenchymal markers (e.g. vimentin, α-smooth muscle actin (α-SMA), desmin, 
(pro)collagen, fibronectin, and fibroblast-specific protein-1), and an invasive phenotype 
(Willis & Borok 2007). 
Nowadays, three different subtypes of EMT have been classified: type 1 EMT generates 
primary mesenchymal cells during embryogenesis and organ development and is thus 
associated with proper morphogenesis; type 2 EMT is associated with wound healing, tissue 
regeneration, and organ fibrosis; and type 3 EMT occurs in neoplastic cells with genetic and 
epigenetic changes affecting oncogenes and tumor suppressor genes (Kalluri & Weinberg 
2009). 
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In lungs, alveolar epithelial cells, and type II pneumocytes in particular, seem to be 
progenitors for mesenchymal cells (Kim et al. 2006). The contribution of EMT to the 
mesenchymal cell accumulation in fibrosis is suggested to be significant: genetic mapping of 
epithelial cells has shown that in experimental models of lung fibrosis, approximately one-
third of fibroblasts are of epithelial origin (Kim et al. 2006; Tanjore et al. 2009). 
The fibrotic EMT in response to TGF-β1 is mediated predominantly via Smad-dependent 
pathways (Gorowiec et al. 2012; Willis & Borok 2007) with a little help at the transcriptional 
level from a selection of transcription factors (e.g. members of the SNAI family and Twist, 
which is a member of the basic helix-loop-helix family; see Table 1) and other repressors and 
activators (Jayachandran et al. 2009; Pozharskaya et al. 2009; Xu et al. 2009). 
 
2.4.3 Myofibroblasts 
An essential and distinctive morphological feature in IPF is the development of the so-called 
fibroblastic foci, represented by widely scattered small aggregates of persistent subepithelial 
fibroblasts and myofibroblasts immersed within extracellular matrix (Pardo & Selman 2002). 
Myofibroblasts are spindle-shaped cells that share features with smooth muscle cells in that 
they are contractile and contain α-SMA stress fibers (Scotton & Chambers 2007). They are 
the primary cell type responsible for the synthesis and deposition of ECM and the resultant 
structural remodelling that leads to the loss of alveolar function (Pardo & Selman 2002; 
Scotton & Chambers 2007). 
The amount of fibroblastic foci is considered a prognostic factor in IPF patients, with a 
positive correlation between mortality and a high score of fibroblastic foci (King et al. 2001; 
Nicholson et al. 2002). 
 
2.4.4 Extracellular matrix 
ECM is a dynamic environment that interacts with cell surface receptors and soluble growth 
factors (Olivieri et al. 2010). It provides cells with support and guidance in essential cellular 
functions such as proliferation, migration, and differentiation (Olivieri et al. 2010; Todorovic 
& Rifkin 2012). Thus, it has an important role in normal tissue formation, homeostasis, and 
repair. This architectural matrix consists of multiple types of proteins, primarily fibronectin, 
collagenous and elastic fibers, fibrillin-containing microfibrils, adaptor proteins, and 
hydrophilic proteoglycans (Olivieri et al. 2010; Todorovic & Rifkin 2012). An intact 
fibronectin matrix is essential in the assembly of e.g. collagen types I and III and fibrillin-1 
into the ECM, suggesting that fibronectin is the master orchestrator for the organization of 
various matrix components (McDonald et al. 1982; Sabatier et al. 2009; Sottile & Hocking 
2002). 
Characteristic for fibrotic lung tissue is the excessive accumulation of ECM, which 
eventually contributes to perturbation of normal tissue architecture and development of 
fibrosis (Eickelberg et al. 2001). Collagens are the most predominant ECM proteins in 
fibrotic lesions (Kuhn et al. 1989), and the increased collagen amount and concentration 
leads to increased tissue stiffness (Cox & Erler 2011). Another group of abnormally abundant 
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proteins in IPF lungs’ ECM are fibronectins, especially a splice variant containing extra type 
III domain A (EDA) (Kuhn et al. 1989; Muro et al. 2008). EDA-containing fibronectin is 
necessary for the differentiation of fibroblasts into myofibroblasts, and it also participates in 
latent TGF-β activation (Muro et al. 2008; Serini et al. 1998). 
 
2.4.5 Signalling molecules 
One of the key factors in fibrogenesis is TGF-β, which is present in excess in fibrotic lungs 
(Khalil et al. 1991). TGF-β has many profibrotic effects (Figure 5): it contributes to 
mesenchymal cell accumulation by promoting EMT as well as fibroblast proliferation and 
transformation into myofibroblasts (Coward et al. 2010), and it also continually induces the 
synthesis of ECM components in fibroblasts and myofibroblasts (Leask & Abraham 2004). 
These profibrotic effects are mediated by both Smad and non-Smad signalling proteins 
(Eickelberg 2001).  
In addition to TGF-β, Wnt is another signalling system related to developmental processes 
and homeostasis. TGF-β and Wnt pathways can interact through p38 and JNK (Akhmetshina 
et al. 2012; Herr et al. 2012). Recently, it has been found that in IPF, the canonical Wnt 
signalling is activated and its interaction with TGF-β is central in the pathogenesis of IPF 
(Akhmetshina et al. 2012; Chilosi et al. 2003). 
Yet another profibrotic effect of TGF-β is its ability to induce gremlin production (Costello et 
al. 2010). Gremlin is a secreted protein which belongs to the DAN family of BMP 
antagonists (Hsu et al. 1998). It has a physiological role during lung development, as it 
balances the expression of BMP-4 and BMP-7 in lung branching morphogenesis (Bellusci et 
al. 1996; Shi et al. 2001). Gremlin is again activated in IPF patients whose mesenchymal 
cells secrete elevated levels of gremlin (Koli et al. 2006; Myllärniemi et al. 2008a; 
Myllärniemi et al. 2008b). It is also suggested to have a role in sarcoidosis, where variation in 
GREM1 gene may predispose patients to pulmonary fibrosis via single nucleotide 
polymorphism in target sequences for miRNAs, which regulate the induction of gremlin 
expression (Heron et al. 2011). 
Gremlin contributes to fibrosis progression by inhibiting BMP signalling (Figure 5) 
(Myllärniemi et al. 2008a). In normal lungs, BMP signalling has a role in basal airway 
homeostasis and it is activated in the adult airway epithelium during regeneration (Masterson 
et al. 2011). Due to reactivated expression of gremlin, BMP signalling is impaired and 
epithelial regeneration processes reduced in IPF patients (Koli et al. 2006). 
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Figure 5. A schematic presentation of the potential roles of the TGF-β and BMP signalling 
pathways in IPF (modified from Koli et al. 2006). The expression of TGF-β is induced during 
early stages of IPF. TGF-β stimulates EMT of alveolar epithelial cells. It also recruits and 
activates fibroblasts which differentiate to myofibroblasts. The persistent myofibroblasts 
overexpress Gremlin, which inhibits BMP-induced regeneration of the epithelium and blocks 
BMP-mediated myofibroblast apoptosis. 
 
2.5 Treatment options for IPF 
There is still no therapy that has been shown to improve survival or otherwise significantly 
modify the clinical course of IPF in all patients. It is thus recommended that patients be 
considered for recruitment to high quality clinical trials of therapy and/or for lung 
transplantation if appropriate (Bradley et al. 2008; Raghu et al. 2011). Because of the lack of 
an effective therapy, new modalities are constantly being sought. Some of the most recent 
and promising clinical trials are presented below and in Table 2. 
There has been some indication of a beneficial effect e.g. for combined triple therapy with 
prednisone (a corticosteroid), azathioprine (an immunosuppressant), and N-acetylcysteine 
(NAC) (an antioxidant) (Demedts et al. 2005). In late 2011, however, the US drug authorities 
released a clinical alert as the results of a NAC study (PANTHER-IPF) showed that this 
widely used three-drug regimen led to a significant increase in mortality and serious adverse 
effects compared to the nontreated group (www.IPFnet.org). Studies for the assessment of 
NAC monotherapy are ongoing (Table 2), and a recent study with early stage IPF patients has 
shown promising beneficial effects in some subgroups of patients (Homma et al. 2012; 
www.IPFnet.org). 
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Pirfenidone (Table 2), the first drug indicated for IPF therapy, was approved in Japan 2008, 
in India 2010, and it became available in Europe in 2011. It has been shown to decrease the 
number of IPF exacerbations, stabilize patient lung function, and the CAPACITY programme 
(Clinical Studies Assessing Pirfenidone in idiopathic pulmonary fibrosis: Research of 
Efficacy and Safety Outcomes) confirmed that pirfenidone has a favourable benefit-risk 
profile (Azuma et al. 2005; Noble et al. 2011; Raghu et al. 1999; Taniguchi et al. 2010). 
Additional clinical trials for evaluation of safety and efficacy of pirfenidone are currently 
recruiting patients (www.clinicaltrials.gov). 
BIBF 1120 is a potent intracellular inhibitor of tyrosine kinase receptors. Its targets include 
platelet-derived growth factor receptors, vascular endothelial growth factor receptors, and 
fibroblast growth factor receptors, which all activate profibrotic signalling pathways 
(Richeldi et al. 2011). A randomized phase II trial showed promising results (Table 2) 
(Richeldi et al. 2011). Studies for long-term safety and efficacy are ongoing 
(www.clinicaltrials.gov). 
Interferon gamma (IFN-γ) is a cytokine secreted by T-helper type I cells. It has been shown 
to inhibit fibroblast proliferation and collagen synthesis (Narayanan et al. 1992; Okada et al. 
1993). Despite the promising results of in vitro and animal model studies, its efficacy 
remained controversial in clinical trials (Table 2) (Bajwa et al. 2005; King et al. 2009; Raghu 
et al. 2004). In these trials, the patients received IFN-γ subcutaneously. A new approach is 
inhaled IFN-γ aerosol, which enables higher concentration of drug delivered to the lung (Diaz 
et al. 2012). 
Pulmonary hypertension is common in IPF patients awaiting lung transplant (Shorr et al. 
2007). The rationale behind the use of sildenafil (Table 2) is to relief the increased vascular 
pressure and hence improve the patients’ exercise tolerance (Jackson et al. 2010). Sildenafil 
inhibits phosphodiesterase type 5 (PDE5) (Corbin & Francis 1999). The pulmonary 
vasodilating effects of nitric oxide are mediated through cyclic guanosine monophosphate, 
which is rapidly degraded by PDE5 (Corbin & Francis 1999; Galie et al. 2005). Thus, 
inhibition of PDE5 by sildenafil enhances the cyclic guanosine monophosphate-mediated 
relaxation of vascular smooth muscle cells and causes pulmonary vasodilation (Ghofrani et 
al. 2002). 
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Table 2. Examples of ongoing clinical trials for finding new treatment options for IPF. 
Drug Mode of action Clinical trials & Results References 
N-acetylcysteine 
(NAC) 
○ stabilizes AEC intracellular 
redox state and preserves 
intracellular glutathione levels 
○ inhibits EMT in vitro 
 
○ in combination with standard therapy, NAC may slow down disease progression. 
However, this did not translate into survival benefit (IFIGENIA study) 
○ one arm of PANTHER trial (conventional therapy + NAC) stopped because of increased 
mortality and serious adverse effects. The two remaining arms of PANTHER phase III trial 
(NAC, placebo) will continue. Results are expected in 2013. 
○ NAC monotherapy may have some beneficial effect in early-stage IPF patients 
Demedts et al. 2005; 
Felton et al. 2009; 
Homma et al. 2012; 
www.IPFnet.org 
  
 
pirfenidone 
○ inhibits collagen synthesis 
○ reduces the number of myo-
fibroblasts and the expression of 
TGF-β 
○ suppresses Smads signalling 
○ prevents acute exacerbation 
○ approved in Japan, India, and Europe for the treatment of IPF 
○ additional clinical trials recruiting patients 
Azuma et al. 2005; Choi 
et al. 2012; Iyer et al. 
2000; Kakugawa et al. 
2004; Raghu et al. 1999 
BIBF 1120 
○ inhibits tyrosine kinase 
receptors 
○ a trend toward a reduction in the decline in lung function, fewer acute exacerbations, and 
preserved quality of life 
○ a trial for continuation of BIBF 1120 treatment for IPF patients is ongoing. Estimated 
study completion in 2015. 
Richeldi et al. 2011; 
www.clinicaltrials.gov 
 
 
Interferon-gamma 
(IFN-γ) 
○ suppresses the level of 
procollagen 
○ downregulates TGF-β over- 
expression 
○ some patients might benefit from treatment with IFN-γ; individual susceptibility could 
determine clinical response. Efficacy remains controversial. 
○ a pilot phase I study of aerosol IFN-γ showed that inhaled IFN-γ is safe and effectively 
delivered to the lung parenchyma; no therapeutic conclusions. 
Bajwa et al. 2005; Diaz 
et al. 2012; Goldring et 
al. 1986; 
Gurujeyalakshmi & Giri 
1995; Luppi et al. 2009; 
Raghu et al. 2004; 
www.clinicaltrials.gov 
Sildenafil 
○ inhibits phosphodiesterase-5  
○ causes pulmonary vasodilation 
○ approved for use in pulmonary arterial hypertension 
○ controversial results with IPF patients, further research needed 
○ a phase IV study is ongoing, estimated study completion in 2013 
Collard et al. 2007; 
Idiopathic Pulmonary 
Fibrosis Clinical 
Research Network et al. 
2010; Jackson et al. 
2010; 
www.clinicaltrials.gov  
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3 EMPHYSEMA 
 
Chronic obstructive pulmonary disease (COPD) is a major global health problem, which is 
predicted to become the 4th most common cause of death in the world by 2030 (Mathers & 
Loncar 2006). It is characterized by airflow obstruction, for which three major mechanisms 
have been implicated: the first is the loss of elasticity and the destruction of the alveolar 
attachments of airways within the lung as a result of emphysema, which results in a loss of 
support and closure of small airways during expiration; the second is the narrowing of small 
airways as a result of inflammation and scarring; and the third is the blocking of the lumen of 
small airways with mucous secretions (Barnes 2004). 
The characteristic lung parenchymal abnormality found in COPD patients is emphysema, 
which represents a reaction of the alveolar space distinct from fibrosis. Histopathologically, 
emphysema is characterized by loss of alveolar structure due to alveolar wall destruction, 
which leads directly to a reduction in total alveolar number and increased airspaces in the 
parenchyma (Fischer et al. 2011). This results in a reduction in the ratio of gas exchange 
surface area to lung volume, and respiratory insufficiency (Morty et al. 2009). 
Emphysema is often accompanied by small airways disease, which includes airway 
inflammation with increased mucus production, airway remodelling, and peribronchiolar 
fibrosis, all contributing to the airflow limitation (Barnes et al. 2003). 
 
3.1 Combined pulmonary fibrosis and emphysema 
It is only recently that the two disorders, emphysema and fibrosis, have been recognized to 
exist in the same lung. This syndrome is called Combined Pulmonary Fibrosis and 
Emphysema (CPFE). There is still controversy about whether CPFE is a unique, distinct 
disease, or simply the coincidental coexistence of the two pathological alterations (Jankowich 
& Rounds 2012; Oliva et al. 2011). In either case, it typically consists of emphysema of the 
upper lung zones and fibrosis of the lower lung zones (Oliva et al. 2011). 
CPFE patients usually have a relatively normal lung volume which is suggested to be based 
on the counterbalancing physiologic forces of hyperinflation in emphysema and restriction in 
fibrosis (Jankowich & Rounds 2012; Oliva et al. 2011). However, patients with CPFE 
demonstrate severe hypoxemia and severely reduced diffusing lung capacity for carbon 
monoxide (Oliva et al. 2011). There is a male predominance in CPFE patients, and a strong 
association with cigarette smoking (Cottin et al. 2005; Jankowich & Rounds 2012). Reported 
median survival has a range of 2-8 years (Jankowich & Rounds 2012). 
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PRESENT STUDY 
4 AIMS OF THE STUDY 
Fibrotic and emphysematous lung tissues are structurally very different: in fibrosis an excess 
of parenchymal cells and ECM is seen, and in emphysematous lung in COPD a marked tissue 
loss is observed. We hypothesised that these diseases represent opposing processes in the 
lung parenchyma, and that alterations in TGF-β signalling in opposite directions 
(upregulation in fibrosis, downregulation in emphysema) is a major contributing factor to 
either tissue loss or accumulation. In addition, we hypothesized that the restoration of  
TGF-β/BMP signalling imbalance could prevent the progression of fibrotic changes in IPF 
patients’ lungs. 
 
The aims of the study were to evaluate the mechanisms of the TGF-β signalling system in the 
human fibrotic lung and, in relation to TGF-β family signalling, to identify potential drug 
candidates for IPF. 
 
In detail the aims were 
 To study TGF-β storage, activation, and signalling properties in IPF. 
 To assess the role of transcription factor GATA-6 in the pathogenesis of IPF, 
specifically as a mediator of TGF-β’s profibrotic signals. 
 To characterize TGF-β signalling in pathologically distinct areas of the human 
lung (production of excessive tissue in fibrosis versus tissue loss in 
emphysema). 
 To search for novel treatment options for IPF by screening chemical compound 
libraries for molecules which could restore TGF-β and BMP signalling 
imbalance. 
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5 MATERIALS & METHODS 
5.1 Patient material 
Lung tissue samples were acquired from patients from the Helsinki University Central 
Hospital. UIP lung biopsies were either diagnostic biopsies or obtained from lung explants 
taken during lung transplantation. COPD was defined according to the GOLD criteria 
(FEV1< 80% of reference, FEV1/FVC < 70% and bronchodilatation effect < 12%). Control 
biopsies were obtained from healthy lung derived from operations in which benign tumours 
were removed. 
All patients received written information and gave their written consent to use the samples. 
The Ethics Committee of the Helsinki University Central Hospital, Department of Internal 
Medicine, approved the study. 
In total, the samples of 32 IPF/UIP patients and 16 COPD patients were used in this study. 
The details of patient age and gender are presented in Table 3. 
 
 
Table 3. Age and gender of the patients studied. 
 IPF/UIP COPD 
Age in years: range (mean ± SD) 34-79 (59 ± 11) 45-75 (58 ± 9) 
Gender: M / F 22 / 10 6 / 10 
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5.2 Cell lines 
The studies were conducted using commercial cell lines obtained from American Type 
Culture Collection (ATCC, Manassas, VA) or Lonza (Basel, Switzerland), primary cell lines 
isolated from patient lung tissue samples, and reporter cell lines (Table 4). 
 
Table 4. Cell lines used in the studies. 
Cell line Characteristics 
CCL-190, CCL-151 normal human lung fibroblasts (ATCC) 
CCL-134 fibroblasts from a patient with IPF/UIP (ATCC) 
CCL-185 A549 human lung carcinoma; epithelial cells (ATCC) 
SAEC human small airway epithelial cells (Lonza) 
UIP-2, -3, -4, -8 primary lung fibroblast cell lines from patients with IPF/UIP 
COPD primary lung fibroblast cell line from a patient with COPD 
BMP reporter cells (Bre)2-luc in pcDNA3 stably transfected to A549 
TGF-β reporter cells (CAGA)12-luc in pcDNA3 stably transfected to A549 
 
 
 
5.2.1 Isolation of primary cell lines 
Lung tissue was washed with PBS and scraped with a scalpel into small pieces. They were 
placed on a cell culture dish in Dulbecco’s modified Eagle’s medium (DMEM) containing 
10% fetal calf serum, 2 mM L-glutamine, and antibiotics. Upon follow-up, fibroblastic cells 
appeared growing either out the tissue pieces or as islets. Dead cells were removed and fresh 
medium added daily for 2-3 days and later twice a week. The average time to first passage 
was 3-4 weeks. For experiments, the cell lines were used between passages 4-10. 
 
5.2.2 BMP and TGF-β reporter cells 
(Bre)2-luc and (CAGA)12-luc in pGL3-Basic vector were provided by Peter ten Dijke (The 
Netherlands Cancer Institute, Amsterdam, The Netherlands). These are BMP- and TGF-β-
responsive elements, respectively, linked to luciferase gene (Dennler et al. 1998; 
Korchynskyi & ten Dijke 2002). KpnI-XbaI fragments from these constructs were cloned into 
pcDNA3 cloning vector’s NruI-XbaI sites. 
For stable transfection, plated A549 cells were transfected o/n with plasmid DNA using 
FuGENE HD (Roche). Selection was started with 1.5 mg/ml of antibiotic G418 sulfate 
(Calbiochem, China) and fresh selection medium changed every 3-4 days. Cells were 
cultivated for 2-3 weeks before isolated clones were picked. For the maintenance of stably 
transfected reporter cells, 0.4 mg/ml G418 was used. 
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5.3 Immunological methods 
5.3.1 Antibodies 
Primary antibodies used in the studies are presented in Table 5. 
 
Table 5. Antibodies used in the studies. 
Antibody Manufacturer Studies 
α-SMA NeoMarkers Inc., Fremont, CA ICC, IF, WB 
Caspase-3 Cell Signalling Technology, Danvers, MA IHC 
Desmin NeoMarkers Inc. ICC 
E-cadherin Invitrogen, Carlsbad, CA IF 
Fibrillin-1 Prof. L. Sakai, Oregon Health and Science University, Portland, OR IHC, PLA 
Fibrillin-2 Millipore, Temecula, CA IHC, PLA 
Fibronectin Sigma, St. Louis, MO PLA 
FOG-2 Santa Cruz Biotechnology, Santa Cruz, CA IHC 
GAPDH Santa Cruz Biotechnology WB 
GATA-4 Santa Cruz Biotechnology IHC 
GATA-6 Santa Cruz Biotechnology ICC, IHC, IF 
Integrin αvβ6 Stromedix Inc., Cambrigde, MA IHC 
Integrin β8 Santa Cruz Biotechnology IHC 
Ki67 Thermo Fisher Scientific, Fremont, CA IHC 
LTBP-1 R&D Systems, Minneapolis, MN IHC, IF, WB, PLA 
LTBP-1 Santa Cruz Biotechnology PLA 
Phospho-Smad2 
(Ser465/467) Millipore IHC, IF 
P-Smad1/5/8 Millipore IHC 
P-Smad1/5/8 Cell Signalling Technology WB 
ICC, immunocytochemistry; IHC, Immunohistochemistry; IF, immunofluorescence; WB, 
western blotting; PLA, proximity ligation assay 
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5.3.2 Immunohistochemistry and immunofluorescence 
Paraffin-embedded tissue sections from lung biopsies were deparaffinized in xylene and 
rehydrated in graded alcohol. Antigens were retrieved by heating the sections in 10 mM 
citrate buffer (pH 6.0) and endogenous peroxidase activity was neutralized with 0.3% 
hydrogen peroxide. Staining for bright field microscopy was performed with Histostain Plus 
Broad Spectrum Kit (Zymed, San Francisco, CA), Vectastain Elite ABC Kit (Vector 
Laboratories, Burlingame, CA), Novolink Polymer Detection System (Novocastra, Leica 
Biosystems Newcastle Ltd., Newcastle Upon Tyne, United Kingdom), or ImmPRESS reagent 
kit (Vector Laboratories, Burlingame, CA) according to the manufacturers´ instructions. The 
sections were exposed to primary antibodies o/n at +4°C or 1 h, RT. Bound antibodies were 
visualized using peroxidase substrates 3-amino-9-ethylcarbazole (Zymed) or 
diaminobenzidine (Sigma or Leica). When needed, the cells and tissue sections were 
counterstained with Mayer’s haematoxylin. 
In immunocytochemical staining, cells were grown on chamber slides (NUNC Lab-Tek, 
Rochester, NY) and fixed with 4% paraformaldehyde (RT) or methanol (-20°C). The staining 
followed the same protocol, except antigen retrieval in RT by 0.1% Tween-20 for 10 min. 
Double staining was carried out using the Histostain Plus Broad Spectrum Kit (Zymed). 
For fluorescence, bound antibodies were visualized using secondary antibodies with either 
green or red fluorescent labels. Cell nuclei were counterstained with 4’,6-diamidino-2-
phenylindole (DAPI). 
In all staining experiments, control samples were treated with goat IgG (Jackson 
ImmunoResearch Laboratories, West Grove, PA), mouse isotype control (Zymed) or rabbit 
isotype control (Zymed). Also a negative control with primary antibody replaced by PBS was 
included in all series of stainings. 
The samples were examined with an Olympus BX51 microscope (Olympus, Tokyo, Japan) 
connected to an Olympus U-RFL-T mercury lamp or Zeiss LSM 510 confocal microscope 
(Carl Zeiss AG, Oberkochen, Germany). 
 
5.3.3 Digital image analysis and quantification of antigen-positive cells 
Immunoreactivity was analyzed using digital image analyses. From each stained tissue 
section, representative images were taken with Olympus U-CMAD3 camera (Olympus, 
Japan) and QuickPHOTO CAMERA 2.1 software (Promicra, Czech Republic). If the area in 
the microscope field did not contain >50% tissue, the slide was moved vertically until a 
representative area was seen. The digital images were dissected to epithelial, parenchymal 
and fibroblastic foci pictures using a cutting knife tool from a digital imaging program 
(Photoshop). The areas of positive and negative staining were calculated using Image-Pro 
Plus 6.1 software (Media Cybernetics, Inc., Silver Spring, MD). 
Alternatively, positive (stained reddish-brown) and negative (stained blue) nuclei were 
counted under the microscope. A hundred nuclei were counted from at least two different 
parts of each tissue specimen, and the average percentage of positive nuclei in each tissue 
sample was used for statistics. 
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5.3.4 Proximity Ligation Assay 
Proximity ligation assay (Olink Bioscience, Uppsala, Sweden) provides a means for protein 
interaction studies in vivo. First, acetone-fixed fresh-frozen sections of human lung were 
incubated o/n at +4°C with two primary antibodies. Secondary antibodies are conjugated with 
DNA probes which, in close proximity, form a closed circle with the added oligonucleotides 
and ligase enzyme. During the rolling-circle amplification reaction, fluorescently labelled 
oligonucleotides are hybridized, resulting in spot-like positive signals indicating that the two 
primary antibodies are bound in close proximity. 
 
5.3.5 Immunoblotting 
Cells were lysed by either sonicating a PBS suspension or using ice-cold lysis buffer (120 
mM NaCl, 0.5% NP-40, 100 mM NaF, 1 mM Na3VO4 in 20 mM Tris-HCl, pH 8.0; protease 
inhibitors added as Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim, Germany)). 
Whole-cell lysates were cleared by centrifugation and assayed for protein content using RC 
DC protein assay (Bio-Rad Laboratories, Hercules, CA). An equal amount of protein per lane 
was used in standard reducing SDS-PAGE (7% or 12%) and transferred to nitrocellulose 
membranes. The membranes were blocked with 10% milk in Tris-buffered saline containing 
0.1% Tween-20, probed with antibody for 1 h, followed by horseradish peroxidase-
conjugated secondary antibody treatment. The enhanced chemiluminescence system 
(Amersham Pharmacia Biotech Europe GmbH, Freiburg, Germany) was used for detection. 
Equal protein loading was ensured by reprobing the membrane for GAPDH. 
 
5.4 Quantification of peribronchiolar fibrosis 
Masson’s trichrome stained paraffin sections were used for the quantification of 
peribronchiolar thickening in lung biopsies. Masson’s trichrome is a standard histological 
staining protocol which stains collagen blue and cellular components red. Photomicrographs 
of bronchioles were taken with Olympus BX51 microscope and analyzed using Image-Pro 
digital image processing software (Media Cybernetics, USA). The proportion of blue staining 
from the total area of bronchiolar tissue was measured. 
 
5.5 TGF-β activity assays 
TGF-β activity was studied with two methods. In study (II), cells were transiently co-
transfected with the (CAGA)12-luciferase promoter construct together with pRL-TK (Renilla 
luciferase control, Promega, Madison, WI) plasmid using the FuGENE HD transfection 
reagent (Roche). After 48h incubation, the cells were lysed and subjected to luciferase 
activity measurements by a Dual Luciferase Kit (Promega) and Digene DCR-1 luminometer 
(MGM Instruments, Hamden, CT). 
In study (III), the relative TGF-β activity of LTBP-1 and control siRNA-transfected cells was 
assayed by coculture with mink lung epithelial cells stably transfected with PAI-1 promoter 
fragment fused to luciferase reporter gene (Abe et al. 1994). 
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5.6 siRNA assays 
The cells were transfected with siRNA for GATA-6 or LTBP-1 (Qiagen sciences, Maryland, 
USA) using Lipofectamine 2000 reagent (Invitrogen). AllStars siRNA (Qiagen) was used as 
a control. The transfection efficiency was analyzed in mRNA and protein expression levels. 
 
5.7 Real-time reverse transcriptase PCR 
Prior to RNA extraction, snap-frozen human lung biopsy samples were homogenized using 
Lysing Matrix D (MPBiomedicals, Solon, OH) and mouse lung tissue samples were crushed 
with a pestle. Total RNA was extracted from cultured cell lines and tissue samples using 
NucleoSpin RNA II kit (Macherey-Nagel GmbH, Düren, Germany) or RNeasy Mini Kit 
(Qiagen, Hilden, Germany). RNA concentration as well as purity was determined using 
NanoDrop (Thermo Scientific, Wilmington, DE) or Agilent 2100 Bioanalyzer at the 
Biomedicum Biochip Center (Helsinki, Finland). RNA was reverse transcribed with iScript 
cDNA synthesis kit (Bio-Rad) or using random hexamer primers (Roche Molecular Systems, 
Inc., or Invitrogen) and MuLV Reverse Transcriptase (Roche) or Superscript III reverse 
transcriptase (Life Technologies, Carlsbad, CA). cDNA was used as a template for PCR 
reactions. 
In real-time RT-PCR, a 64 bp fragment of human GATA-6 gene was amplified with primers  
5´-AGAAACGCCGAGGGTGAAC-3´ (forward) and 5´-GCACCCCATGGAGTTTCATG-
3´ (reverse) (Oligomer, Helsinki, Finland) using Power SYBRGreen PCR Master Mix 
(Applied Biosystems, Warrington, UK). α-SMA, Col1A1, Col3A1, CTGF, fibrillin-1, 
fibrillin-2, fibronectin, gremlin-1, Id1, Id3, LTBP-1, LTBP-3, LTBP-4, TGF-β1-3, and PAI-1 
analyses were carried out using TaqMan Assays-On-Demand gene expression products 
(Applied Biosystems) and the ABI 7500 FAST System (Applied Biosystems) or Bio-Rad 
CFX96 system (Bio-Rad). Human 18S rRNA and human or mouse tata-binding protein 
(TBP) with TaqMan Universal PCR Master Mix (Applied Biosystems) were used as 
reference genes. The relative gene expression differences were calculated with the 
comparative ∆∆CT method. 
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5.8 High-throughput screening 
BMP and TGF-β reporter cells were suspended in phenol red-free DMEM (Gibco, Grand 
Island, NY) with supplements, seeded on white 384-well plates and allowed to attach. The 
screening of chemical compound libraries (MicroSource Spectrum Collection (Microsource 
Discovery Systems, Inc., Gaylordsville, CT) and FDA approved drug library (Enzo Life 
Science, Farmingdale, NY)) was performed in high throughput center with the Institute for 
Molecular Medicine Finland (FIMM). First, reporter cells were treated with these compounds 
for 18 h at 37°C: for MicroSource library, 20 µM concentration was used; for the Enzo 
library, the compounds were tested over 10 nM-10 µM concentration range. Following the 
incubation, the cells were lysed and luciferase activity measured using SteadyLite Plus 
reagent (PerkinElmer, Waltham, MA). Positive controls (BMP-4 and TGF-β1) and a negative 
control (DMSO) were included in the experiments. 
 
5.9 Mouse studies 
Mouse studies were approved by the regional state administrative agency of Southern Finland 
(permission # ESAVI/871/04.10.03/2012). The animals were kept in animal facility with 
modern equipment, and received food, fresh water and humane care. 
6-week-old male C57b6J mice were divided into three groups (8-12 mice per group). One 
experimental group of unexposed animals represented non-treated controls. For the other two 
experimental groups, silicon dioxide (SiO2; 50 mg/ml in sterile PBS) was administered 
according to the protocol described previously (Lakatos et al. 2006). Two subsequent 
oropharyngeal aspiration doses were given to the animals on day 1 and day 8 of the 
experiment to ensure even exposure of all animals. The animals were sedated with isoflurane 
for the aspiration of silica suspension and euthanised with carbon dioxide at the time of 
sacrifice. 
The effect of tilorone dihydrochloride (Sigma) was studied in one experimental group of 
mice exposed to SiO2. The drug was administered intraperitoneally at a dose of 50 mg/kg 
(Golovenko & Borisyuk 2005; Mayer-Sonnenfeld et al. 2008; Zinkovsky et al. 2007) every 
three days for 30 days, starting from day 1 immediately after the first SiO2-inhalation was 
received. The frequency of drug administration was chosen based on half-time of tilorone 
clearance [t½ (lungs) = 65 h] (Golovenko & Borisyuk 2005). 
Bronchoalveolar lavage fluid was obtained from the euthanised mice by cannulating the 
trachea and lavaging with 2x300 µl of PBS. The total cell number of bronchoalveolar lavage 
fluid was calculated using BIO-RAD TC10 automated cell counter (Singapore). Differential 
cell counts of macrophages, neutrophils, and lymphocytes were obtained by microscopy of 
May-Grünwald-Giemsa-stained cytocentrifuge preparates. 
Lung tissue from the left-side lungs was fixed with 4% paraformaldehyde, embedded in 
paraffin, and sectioned. Histological evaluation fibrosis and inflammation was performed 
from haematoxylin and eosin stained sections. The frozen right lung was placed in liquid 
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nitrogen and crushed with a pestle until completely pulverized. The homogenized tissue 
powder was used for mRNA analyses and the hydroxyproline assay. 
The hydroxyproline assay was performed in order to assess the collagen content of the lung 
tissue. Proteins were precipitated by incubating samples with trichloroacetic acid on ice. 
Hydrolysis of the precipitate was completed by addition of 37% HCl and heating at 110°C 
until the samples were charred and dry. The dried pellet was reconstituted with water and 
assayed for hydroxyproline content using chloramine-T as previously described (Reddy & 
Enwemeka 1996). 
 
5.10 Statistical analyses 
Data were analyzed with SPSS 15.0, PASW 18.0 (SPSS, Chicago, IL), and IBM SPSS 
statistics versions 19.0 and 20.0 (IBM, Armonk, NY) using the non-parametric Kruskal-
Wallis and Mann-Whitney tests. A P value of <0.05 was considered to be statistically 
significant. 
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6 RESULTS 
6.1 Protein localization in IPF/UIP tissue 
Immunohistochemistry was performed to study the localization of proteins linked to cell 
differentiation (transcription factors GATA-4 and GATA-6, and their cofactor Friend Of 
GATAs (FOG)-2), cell cycle (proliferation marker Ki67, apoptosis marker Caspase-3), TGF-
β storage (LTBP-1), TGF-β activation (integrins αvβ6 and β8), TGF-β signalling activity 
(signal transducer P-Smad2), and ECM components (fibrillin-1 and fibrillin-2) in control 
samples and different compartments (epithelium, parenchyma, fibroblastic foci) of the 
IPF/UIP samples (studies I, III). A summary of the results is presented in Table 6. 
 
Table 6. Protein localization in IPF/UIP and control tissue samples. 
  epithelium parenchyma fibroblastic 
foci 
controls 
transcription 
factors 
GATA-4 + + - N/A 
GATA-6 + + + N/A 
FOG-2 + + - N/A 
proliferation  
& apoptosis 
Ki67 + + - + 
Caspase-3 + + - + 
TGF-β 
storage, 
activation, 
and 
signalling 
activity 
LTBP-1 + + + + 
integrin αvβ6 + - - (+) 
integrin β8 (+) (+) (+) (+) 
P-Smad2 + + + + 
ECM 
proteins 
fibrillin-1 - (+) + + 
fibrillin-2 - (+) + + 
+, protein expression; (+), very low level of protein expression; -, no protein expression; N/A, 
not analyzed 
 
 
6.2 TGF-β signalling  
6.2.1 The expression of TGF-β isoforms in IPF/UIP and COPD tissue 
The mRNA expression levels of all TGF-β isoforms (TGF-β1, TGF-β2, and TGF-β3) were 
analyzed from control, IPF/UIP, and COPD tissue samples (studies II, III). It was found that 
all TGF-β1-3 isoforms were expressed in lung tissue but in all study groups, TGF-β1 was 
clearly the most abundantly expressed isoform. There were no significant differences in 
expression levels when IPF/UIP and COPD samples were compared to normal lung samples. 
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6.2.2 LTBP-1 upregulation, interactions with ECM proteins, and functional role in 
IPF/UIP 
Latent TGF-β binding proteins (LTBPs) play a critical role in the assembly, secretion, storage, 
and activation of TGF-β. When the mRNA expression levels of latent TGF-β-interacting 
LTBP isoforms (LTBP-1, -3, and -4) were analysed in IPF/UIP and control tissue samples 
(study III), it was discovered that all of these isoforms were expressed in lung tissue. 
However, LTBP-1 mRNA levels were significantly upregulated in IPF/UIP tissue compared 
to control samples. There was also a strong upregulation and accumulation of LTBP-1 protein 
in IPF/UIP tissue compartments. 
The accumulation of extracellular matrix (ECM) is a characteristic feature of IPF. LTBP-1 
binds to fibronectin and fibrillins, and these LTBP/ECM interactions play a role in TGF-β 
activation processes. Thus, the expression levels of fibronectin, fibrillin-1, and fibrillin-2 were 
studied in control and IPF/UIP tissue samples (study III). Compared to controls, the mRNA 
expression levels of all of these ECM-related genes were found to be significantly upregulated 
in IPF/UIP tissue samples (P(fibronectin)=0.009; P(fibrillin-1)=0.016; P(fibrillin-2)=0.014). 
These genes were expressed in the following order of abundance: fibronectin > fibrillin-1 > 
fibrillin-2. 
Fibrillin-1 and fibrillin-2 proteins were found mainly in the areas on fibroblastic foci of 
IPF/UIP tissue samples (Table 6). LTBP-1 was shown to be in close proximity, i.e. associate, 
with fibronectin, fibrillin-1, and fibrillin-2 in IPF/UIP tissue samples. 
The functional role of LTBP-1 was studied by siRNA-mediated silencing. The results of 
normal lung fibroblasts (CCL-190) and epithelial cells (SAEC) were, however, the opposite. 
In fibroblasts, reduced LTBP-1 expression led to increased TGF-β activity and also increased 
mRNA expression levels of TGF-β target genes connective tissue growth factor (CTGF), 
plasminogen activator inhibitor-1 (PAI-1), and collagen 1A1 (Col1A1). In epithelial cells, 
there was a decrease in TGF-β activity as well as mRNA expression levels of the above-
mentioned TGF-β target genes. 
 
 
6.2.3 Active TGF-β signalling in fibrotic and emphysematous lung tissue 
As an indicator of active TGF-β signalling, the expression of the phosphorylated, i.e. 
activated, form of TGF-β signal transducer Smad2 (P-Smad2) was analyzed in both COPD 
and IPF/UIP tissue samples (studies II, III). 
Compared to control samples, the emphysematous areas of the COPD samples showed a 
significant decrease in the number of P-Smad2 positive nuclei in alveolar epithelium  
(P = 0.006); there was also a small decrease in the bronchiolar epithelium. Furthermore, a 
weakened staining intensity was observed in the more severe stages of COPD. In contrast, the 
increased fibrotic tissue found outside the bronchioles in COPD samples showed significantly 
higher proportions of P-Smad2 positive nuclei. 
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In the fibrotic samples of IPF patients, P-Smad2 was expressed in the fibroblastic foci, in the 
thickened epithelium overlying the fibroblastic foci, and in the parenchyma (Table 6). There 
was more P-Smad2 positivity in IPF/UIP samples when compared to controls (P = 0.008). 
In summary, emphysematous tissue showed decreased and fibrotic tissue increased TGF-β 
signalling activity. 
 
6.2.4 GATA-6 mediates cell differentiation towards a myofibroblastic phenotype 
Fibroblastic cell lines isolated from IPF/UIP patients’ tissue samples were found to express 
mRNA for transcription factor GATA-6 and myofibroblast marker α-SMA, but there was no 
pattern in expression levels. On protein level, GATA-6 was shown to colocalize with α-SMA 
in the same cells in fibroblastic foci of IPF/UIP tissue samples. 
A primary fibroblastic cell line with an abundant GATA-6 expression was selected for siRNA 
studies (study I). In non-treated fibroblasts, TGF-β caused a notable increase in the mRNA 
expression levels of GATA-6 and α-SMA, and also a minor increase in ECM components 
collagen and fibronectin expression. In contrast, in cells with a reduced GATA-6 expression 
due to siRNA treatment, TGF-β had virtually no effect on the expression of the genes 
mentioned above. 
In IPF/UIP tissue samples, GATA-6 was expressed also in the epithelial cells (Table 6). The 
differentiation of epithelial cells towards a mesenchymal phenotype, i.e. epithelial-
mesenchymal transition (EMT), is suggested to be a central mechanism in the pathogenesis of 
IPF/UIP (Willis & Borok 2007). Thus, the possible relationship of GATA-6 expression and 
EMT was examined in vitro in human A549 pulmonary epithelial cells, which do not 
spontaneously express GATA-6 (Vähätalo et al. 2011) but are known to undergo EMT when 
induced with TGF-β1 (Kasai et al. 2005). 
A549 cells were transiently transfected with an expression plasmid containing human GATA-
6 cDNA. These cells started to express GATA-6 and myofibroblast marker α-SMA. Control 
cells transfected with a corresponding empty plasmid, i.e. without GATA-6 gene, were 
negative for both GATA-6 and α-SMA. In comparison, A549 epithelial cells were stimulated 
with TGF-β1 for the induction of EMT, which was characterized by loss of expression of 
epithelial marker E-cadherin and simultaneous increase in the expression of α-SMA. It was 
also noted that during this process, GATA-6 was expressed. 
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6.3 High-throughput screening 
6.3.1 In vitro 
Since there is a known imbalance of BMP and TGF-β signalling in IPF (BMP decreased, 
TGF-β increased), we hypothesized that restoration of BMP signalling could be one strategy 
for the prevention of fibrosis progression or even treatment of fibrosis. 
In study (IV), BMP- and TGF-β-responsive reporter cell lines were used in high-throughput 
screening of two commercial, partially overlapping, chemical compound libraries 
(MicroSource Spectrum Collection (ca. 2000 chemical compounds) and Enzo Life Science’s 
FDA approved drug library (640 chemical compounds)). 
Primary hits were selected based on pre-defined hit criteria: compounds inducing a minimum 
of 1.5-fold increase of BMP reporter cells; compounds causing a decrease or no effect on 
TGF-β reporter cells; compounds that are non-toxic; compounds that can be administered to 
experimental animals and humans. Based on these criteria, there were seven chemical 
compounds regarded as primary hits in MicroSource collection; screening of the smaller Enzo 
library revealed only one primary hit which had already been detected in the MicroSource 
collection. 
Validation of the primary hit data revealed that only two of these compounds, tilorone (TIL) 
and 2’,3-dihydroxy-4,4’,6’-trimethoxychalcone (CHAL), showed consistent BMP reporter 
activation (Figure 6). In A549 pulmonary epithelial cells, tilorone was shown to cause a 
sustained induction in the expression of BMP target gene inhibitor of DNA 
binding/differentiation (Id)-3. It also induced the expression of BMP-7. 
 
 
 
Figure 6. A representative figure of primary hit validation of chemical compound screening. 
The figure shows the relative activity of both reporter cell lines when exposed to chemicals at 
10 µM concentration. Control is set to 1 (marked with a horizontal line). Tilorone (TIL) and 
2’,3-dihydroxy-4,4’,6’-trimethoxychalcone (CHAL) show consistent activation of BMP 
reporter cell line and a decrease in TGF-β reporter cell activity. 
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6.3.2 Mouse studies 
Because tilorone showed a favourable and sustained effect on BMP signalling in vitro, its 
biological effects were studied in a mouse model of SiO2 (silica)-induced fibrosis. 
On tissue level, the silica-induced fibrotic response was seen as an increase in the amount of 
lung hydroxyproline and mRNA expression levels of collagen and fibronectin. Compared to 
non-treated controls, silica-exposed mice also showed decreased P-Smad1 and increased P-
Smad2 immunoreactivity, reflecting active BMP and TGF-β signalling, respectively. In 
tilorone-treated mice, all of these effects were partially reversed. 
Histological evaluation of silica-exposed mice showed that there were less fibrotic changes 
and lung tissue infiltrating inflammatory cells in tilorone-treated mice. However, tilorone was 
not found to cause any statistically significant changes in total or differential cell counts of 
bronchoalveolar lavage fluid samples.  
In summary, tilorone showed biologically significant antifibrotic properties in a mouse model 
of pulmonary fibrosis. 
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7 DISCUSSION 
 
The aims of this thesis were to characterize TGF-β signalling activity in pathologically 
distinct areas of the human lung; to study TGF-β storage, activation, and signalling properties 
in IPF; and also to search for novel treatment options for IPF. 
The results revealed several novel findings. Although numerous studies have inferred that 
emphysematous tissue may have inadequate TGF-β signalling, it was shown here that Smad-2 
phosphorylation, an indication of active TGF-β signalling, is greatly decreased in 
emphysematous lung tissue. In fibrosis, we challenged the common belief that fibroblastic 
foci consist of actively proliferating cells, showed that TGF-β profibrotic signalling, at least in 
terms of cells’ mesenchymal differentiation, is dependent on GATA-6 transcription factor 
and, for the first time, high-throughput screening was used in IPF research. The results serve 
as a platform for further studies on human fibrosis treatment options. 
 
7.1 The cells in fibroblastic foci are in a quiescent state 
It is a common belief that the fibroblastic foci in IPF consist of actively proliferating cells. 
Cool et al. (2006) have shown that these foci are not the result of malignant proliferation of a 
monoclonal population of fibroblasts, but rather suggested to be formed by heterogeneous 
group of fibroblasts. Here, we showed that even though the proliferation marker Ki67 and 
apoptosis marker Caspase-3 were abundantly expressed in lung parenchyma and epithelium, 
they were absent in fibroblastic foci (Table 6), suggesting that the cells in fibroblastic foci are 
actually in a quiescent state. 
 
7.2 TGF-β storage in EMC structures and integrin-mediated activation 
The deposition of latent TGF-β and BMP in the ECM regulates the local signals of these 
cytokines (Olivieri et al. 2010; Sengle et al. 2008). Numerous studies have reported that 
LTBP-1 binds to fibronectin and fibrillins in vitro and in some tissues also in vivo (Dallas et 
al. 2000; Dallas et al. 2005; Isogai et al. 2003; Ono et al. 2009; Raghunath et al. 1998; 
Taipale et al. 1996). Fetal lung tissue has shown co-distribution of LTBP-1 and fibrillin 
(Isogai et al. 2003) but the novel in vivo findings of this study showed that also in human 
fibrotic lung tissue, LTBP-1 is in close proximity, i.e. associated, with fibronectin, fibrillin-1, 
and fibrillin-2. In addition, we showed that LTBP-1 is targeted to different ECM structures in 
specific areas of the IPF/UIP lung: colocalization of LTBP-1 and fibrillin-1 was found 
throughout the tissue, including epithelial cells, whereas interactions of LTBP-1 and 
fibronectin were abundant only in the parenchymal tissue immediately below the epithelial 
cells. Similar results of LTBP-1 interactions with fibronectin and fibrillin-1 in mouse lung 
tissue have recently been published (Zilberberg et al. 2012).  
Integrin-mediated TGF-β activation is suggested to be important in the pathogenesis of IPF 
(Goodwin & Jenkins 2009). In line with the results of Horan et al. (2008), we found intense 
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immunoreactivity of integrin αvβ6 in epithelial cells in IPF/UIP tissue, likely reflecting 
epithelial damage (Breuss et al. 1995) and contributing to TGF-β activation in the epithelial 
cells. The expression of integrin β8 was scarce throughout the tissue. Since the parenchymal 
areas were found to be rich with latent TGF-β, it is plausible that there are also local 
mechanisms for latent TGF-β activation. These mechanisms, however, are still to be 
discovered in future research. 
 
7.3 TGF-β signalling in pathologically distinct areas of the human lung 
P-Smad2 was studied as an indicator of active TGF-β signalling. In emphysema, alveolar 
structures are destroyed (lack of ECM and cells); in contrast, fibrotic areas represent 
thickening of parenchyma (an excess of ECM and cells). The present studies revealed 
decreased and increased P-Smad2 expression, respectively.  
In a Smad-3 knockout mouse model, impaired TGF-β signalling leads spontaneously to 
increased airspace enlargement and development of emphysema (Bonniaud et al. 2004). In 
human COPD samples, single-nucleotide polymorphism in the TGF-β1 gene is associated 
with COPD (Celedon et al. 2004) and it has also been discovered that several factors related 
to TGF-β signalling (e.g. GDF-10, LTBP-1, inhibitory Smad proteins, and TGF-β receptors 1 
and 2) are downregulated (Ezzie et al. 2012; Pons et al. 2005; Springer et al. 2004; 
Zandvoort et al. 2006). This results in the decreased production of ECM components and 
ineffective repair response to damage of the lung, ultimately resulting in an active 
emphysema process (Gauldie et al. 2006; Zandvoort et al. 2006). Our result of a decreased 
TGF-β signalling activity in human emphysematous lung tissue is in line with these studies. 
Opposite results have also been reported: Koenders et al. (2009) have found increased TGF-β 
staining in human emphysematous lung tissue. However, they used an antibody that 
recognizes both latent and active TGF-β, i.e. the ratio of these two forms remained unknown. 
The activity of TGF-β signalling is mainly regulated on the level of latent TGF-β activation, 
not mRNA/protein expression. The in vivo finding that fibrotic tissue areas showed 
accumulation of LTBP-1 and increased TGF-β signalling activity is in line with previous 
reports of excessive TGF-β expression in IPF and COPD fibroblasts (Koli et al. 2006; Togo 
et al. 2008). 
 
7.4 TGF-β downstream signalling 
In normal human lung tissue, TGF-β1 is expressed in a variety of cells, most profoundly in 
bronchiolar epithelium and alveolar macrophages, but also in mesenchymal and endothelial 
cells (Coker et al. 1996). In the fibrotic lung, TGF-β responsive cells were found throughout 
the tissue: in epithelium, parenchyma, and also in the highly differentiated myofibroblasts in 
fibroblastic foci. Myofibroblast are the primary cell type responsible for the synthesis and 
deposition of EMC and the resultant structural modelling that leads to the loss of alveolar 
function (Pardo & Selman 2002; Scotton & Chambers 2007). Even though the myofibroblasts 
in fibroblastic foci seem to be in a quiescent state, i.e. non-proliferating and non-apoptotic, 
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they still retain responsiveness to TGF-β signals, hence contributing to the ECM 
accumulation.  
Zhang et al. (2008) have shown that the role of transcription factor GATA-6 in lung 
epithelium is to participate in the regeneration process through regulation of bronchioalveolar 
stem cell expansion and differentiation. In agreement with this, GATA-6 expression was 
observed in epithelial cells of IPF lung tissue, and it was expressed during EMT-related 
changes. EMT, in general, is dependent on TGF-β activation (Chapman 2011). However, 
there are numerous factors influencing this process, both on the level of Smad signalling as 
well as additional transcriptional regulators. Here, we added one more factor to this list: 
transcription factor GATA-6 mediates TGF-β signals in EMT.  
It is virtually impossible to distinguish EMT-derived fibroblasts from other fibroblasts in 
humans in vivo. It has been documented that IPF/UIP lung biopsies contain cells which have 
both epithelial and mesenchymal features, suggesting that some degree of EMT occurs in vivo 
during fibrogenesis (Chapman 2011; Kim et al. 2006). This is supported by evidence of in 
vivo EMT in experimental animal models of pulmonary fibrosis (Kim et al. 2006; Tanjore et 
al. 2009). 
 
7.5 High-throughput screening 
High-throughput screening is a widely used tool in modern drug discovery. It refers to the 
possibility of conducting a large number of e.g. chemical or pharmacological tests in a very 
short period of time. This is done by the use of robotics, miniaturized assays, automated liquid 
handling, and sensitive detectors. Cell-based assays have the advantages of predictability and 
possibility of automation and the sensitivity of reporter gene assays also makes them ideal for 
miniaturization; the disadvantages of this set-up are long response time of the reporter system 
and the possible interference from other cellular pathways (Michelini et al. 2010). Thus, it is 
important to verify the effects of primary hit chemicals by other means, both in vitro and in 
vivo. 
In this study, the chemical compound libraries used for high-throughput screening contained 
mostly Food and Drug Administration (FDA)-approved drugs. These are compounds whose 
safety has already been studied in humans. Hence, a potential alternative use of an existing 
and authority-approved drug molecule represents a fast track in the search of novel treatment 
options. 
There are many different animal models of IPF in research use today: fibrosis can be 
experimentally induced by e.g. bleomycin, silica, asbestos, radiation, viral vector delivery of 
transgenes, or transgenic models can be used (Degryse & Lawson 2011). All of these models 
have slightly different features with strengths and weaknesses regarding the fibrotic response, 
which affects the choice of the model used. In this study, we used a mouse model of silica-
induced fibrosis. It was chosen because it resembles human IPF in terms of gremlin 
upregulation which leads to perturbed BMP/TGF-β signalling balance. We did not choose the 
more commonly used bleomycin model due to the fact that this model represents a temporary 
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inflammatory response with a partially reversible fibrosis (Moeller et al. 2008) and thus the 
results may not be applicable to human disease. In fact, according to a review article 
published in 2008 (Moeller et al.), there are over 200 compounds which have shown 
beneficial antifibrotic effects in the bleomycin model of pulmonary fibrosis. To date, only one 
of them, pirfenidone, has been accepted to be used as a therapeutic agent in human IPF. 
TGF-β’s central role in fibrogenesis makes it an attractive target for drug therapy, and e.g. 
anti-TGF-β antibodies and TGF-β inhibitor peptides have been studied (Arribillaga et al. 
2011; Datta et al. 2011). However, as TGF-β also regulates key homeostatic functions, 
interfering with TGF-β signalling may result in highly undesirable side effects (Datta et al. 
2011). The other side of the coin is restoration of BMP signalling, which has shown to 
decrease experimentally-induced fibrosis (Myllärniemi et al. 2008a; Sugimoto et al. 2012). In 
this study, tilorone was shown to enhance BMP signalling, but it is also a known interferon 
inducer (Mayer & Krueger 1970). IFN-γ is suggested to have antifibrotic effects but the 
results of clinical trials have been controversial (Datta et al. 2011). 
The retrospective power analysis (one-sided test, 0.05 significance) gave the animal 
experiment with tilorone ~ 70% power. It is possible that bigger study groups might have 
given more reliable results but, on the other hand, the data obtained here offers a promising 
starting point for further studies with e.g. tilorone analogues. 
 
7.6 Sample selection and methodological aspects 
The tissue samples were either diagnostic biopsies or obtained from lung explants taken 
during lung transplantation. The latter samples represent a selected population: due to 
transplantation criteria, these patients are e.g. generally younger than average IPF patients 
and they are non-smokers. 
In a tissue sample, there are always pathologically distinct areas included. Even though gene 
expression levels can be roughly analyzed in vivo using tissue samples, in vitro analyses from 
selected cell lines can give more reliable results. Total mRNA levels in a tissue do not reveal 
any information about the localization of the protein expression, which is why parallel 
immunostaining was also performed.  
Traditionally, the use of fresh-frozen tissue sections has been the standard for 
immunohistochemical analyses. However, it has been shown that formalin-fixed, paraffin-
embedded tissue sections with antigen retrieval can give just as good – or even better – 
results (Shi et al. 2008). In this study, paraffin-embedded tissue sections were used for 
standard immunohistochemistry and immunofluorescence. Fresh-frozen tissue samples were 
used for proximity ligation assays. 
The primary fibroblast cell lines were isolated from patient tissue samples. Originally these 
fibroblasts represent a heterogeneous population of cells, including myofibroblasts, but also 
non-differentiated ‘normal’ fibroblasts. As shown in study (I), the cells in fibroblastic foci do 
not seem to proliferate, but rather be in a quiescent state, and thus they are probably not the 
dominating subpopulation in the primary fibroblast cell cultures. 
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A549 cells are widely used and profoundly characterized lung cells that originate from type II 
cells. The use of A549 as a model of lung alveolar epithelial cells (AEC) has been criticized, 
due to their malignant origin of lung carcinoma. Commercial cell lines with better AEC II 
characteristics are available but unfortunately they are not human cell lines. Thus, in these 
studies (I, IV), A549 cells were chosen based on their human origin. 
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8 CONCLUSIONS 
 
This thesis provides an overview on TGF-β signalling in two human lung parenchymal 
diseases - idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. The aim 
of the study was to examine alterations in active TGF-β signalling, characteristic to 
pathologically distinct areas of damaged lung tissue. Furthermore, the aim was to study  
TGF-β storage and activation as well as the role of transcription factor GATA-6 in the 
pathogenesis of IPF. Also, new possibilities for the treatment of IPF were sought. 
In conclusion, this study showed that TGF-β signalling activity varies within pathologically 
distinct areas of the lung, with emphysematous areas showing decreased and fibrotic areas 
showing increased signalling activity. In IPF, the increased TGF-β signalling activity is 
accompanied by massive upregulation in the expression of latent TGF-β binding protein 
(LTBP)-1, which was found to be associated with fibronectin and fibrillins in the extracellular 
matrix. 
It is generally believed that fibroblastic foci in IPF consist of actively proliferating cells. 
Here, this view was challenged as the areas of fibroblastic foci were found to be completely 
negative for markers of proliferation and apoptosis. This indicates that the cells are in a 
quiescent state and that an antiproliferative approach may not be a reasonable therapeutic 
target. However, the highly differentiated myofibroblasts in fibroblastic foci still retained 
responsiveness to TGF-β signals, suggesting that they keep contributing to the ECM 
accumulation. 
Transcription factor GATA-6 was expressed in fibroblastic foci and it seems to act as a 
crucial mediator in the TGF-β-induced process of cellular differentiation of fibroblasts and 
epithelial cells towards a myofibroblast-like phenotype. As TGF-β is considered to be a 
ubiquitously expressed cytokine responsible for various tissue homeostatic events, 
downstream factors, such as transcription factors responsible for cells’ mesenchymal 
differentiation, might serve as potential targets for drug therapy. 
For the first time in IPF research, high-throughput screening technique was utilized in the 
search for new therapeutic chemical compounds. The idea was to find a molecule which 
targets the aberrant TGF-β family signalling found in IPF. The most promising candidate drug 
identified, tilorone, showed biologically significant antifibrotic properties in a mouse model 
of pulmonary fibrosis. The data obtained here provides a starting point for further studies with 
e.g. tilorone analogues. 
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